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Abstract
Helicobacter pylori resistance to antimicrobial agents is steadily increasing. It is extremely important to be aware of the local prevalence of
antibiotic resistance so as to adjust treatment strategies. During this single-centre, prospective study, we aimed to determine primary and
secondary resistance rates of H. pylori to antibiotics as well as host and bacterial factors associated with this problem. Overall, 180 patients
(131 female; mean age 43.4  13.5 years; primary resistance 103; secondary resistance 77) with positive 13C-urea breath test were
submitted to upper endoscopy with gastric biopsies. Helicobacter pylori was cultured and antimicrobial susceptibility was determined by
Etest and molecular methods. Clinical and microbiological characteristics associated with resistance were evaluated by logistic regression
analysis. Among the 180 isolates 50% were resistant to clarithromycin (primary 21.4%; secondary 88.3%), 34.4% to metronidazole (primary
29.1%; secondary 41.6%), 33.9% to levoﬂoxacin (primary 26.2%; secondary 44.2%), 0.6% to tetracycline and 0.6% to amoxicillin. Being
female was an independent predictor of resistance to clarithromycin and metronidazole. Previous, failed, eradication treatments were also
associated with a decrease in susceptibility to clarithromycin. History of frequent infections, ﬁrst-degree relatives with gastric carcinoma
and low education levels determined increased resistance to levoﬂoxacin. Mutations in the 23S rRNA and gyrA genes were frequently found
in isolates with resistance to clarithromycin and levoﬂoxacin, respectively. This study revealed that resistance rates to clarithromycin,
metronidazole and levoﬂoxacin are very high and may compromise H. pylori eradication with ﬁrst-line and second-line empiric triple
treatments in Portugal.
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Introduction
Helicobacter pylori is responsible for multiple gastric pathologies
[1]. The universally accepted empiric triple treatment
for H. pylori comprises proton-pump inhibitors (PPI), clari-
thromycin and amoxicillin or metronidazole [1]. However, the
efﬁcacy of the ‘legacy’ triple therapy has decreased in the last
decades and is now inferior to 80% in many countries [1,2].
There are many reasons for therapeutic failure including poor
compliance, inadequate dose/duration of therapy, rapid metab-
olism of PPI, ineffective penetration of antibiotics into the
gastric mucosa, antibiotic inactivation by low gastric pH and,
most importantly, H. pylori resistance to antimicrobial agents
[3,4]. Excessive and indiscriminate use of antibiotics is leading
to decreased susceptibility of H. pylori to such drugs [5].
Resistance of H. pylori to antibiotics is common in clinical
practice but we must distinguish primary from secondary
resistance. Exposure of H. pylori to antibiotics during eradica-
tion attempts can select bacterial resistance. This occurs
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mainly with clarithromycin and levoﬂoxacin but also with
nitroimidazoles. Reports about primary resistance are com-
mon but data after therapeutic failure is scarcer because
patients previously exposed to anti-H. pylori treatment are
frequently excluded from susceptibility studies [6,7].
Prevalence of H. pylori infection in Portugal is 84.2%, 66.2%
and 31.6% for adults, teenagers and children, respectively [8–
10]. In 2012 the estimated age-standardized incidence and
mortality rates for stomach cancer in Portugal were still some
of the highest in Europe [11]. For this reason, H. pylori will
continue to represent a major healthcare problem in this south
European country. The European multicentre studies of in vitro
antimicrobial resistance revealed that in Portugal primary H.
pylori resistance rates to clarithromycin, levoﬂoxacin and
metronidazole were 31.5%, 26.3% and 33.3%, respectively
[5,7]. However, there is little information concerning second-
ary resistance rates and to our knowledge there are no data
about this problem in the central region of the country.
The focus of the present study was to evaluate primary and
secondary resistance rates of H. pylori to antimicrobials in this
region of Portugal. As a secondary objective, we intended to
establish potential host and bacterial factors associated with
resistance to each one of the tested antibiotics.
Patients and Methods
Patients
In this single-centre study patients with dyspepsia, iron-deﬁ-
cient anaemia, need for chronic therapy with PPI and/or
ﬁrst-degree relatives with gastric carcinoma were prospec-
tively considered for inclusion, from September 2009 to
October 2013. All of them had a positive 13C-urea breath test.
Exclusion criteria were: age <18 years; pregnancy; lactating
and/or fertile women who were not using safe contraceptive
methods; history of allergy/hypersensitivity to any antibiotic or
PPI; previous gastric malignancy and/or gastric surgery; current
use of anticoagulants; marked thrombocytopenia; systemic
severe disease; use of antibiotics in the last 4 weeks or PPI in
the last 2 weeks.
Patients were divided into two groups: Group I—no previous
H. pylori eradication treatment (primary resistance); Group II—
previous, failed H. pylori therapy (secondary resistance).
Study design
All patients were submitted to upper endoscopy with biopsies
in the antrum and corpus that were immediately placed in
independent containers of adequate transport media—
Portagerm pylori (bioMerieux Portugal, Linda-A-Velha,
Portugal)—at 4°C, and sent to the microbiology laboratory.
Urease test and Gram staining of a smear prepared from the
biopsy specimen conﬁrmed the presence of H. pylori. After
manual grinding with disposable material the samples were
distributed directly in agar pylori (bioMerieux Portugal,
Linda-A-Velha, Portugal). Cultures were incubated for a mini-
mum of 72 h and a maximum of 10 days at 37°C under
microaerobic conditions, produced with H2-CO2-generating
packs (GENbag, bioMerieux Portugal, Linda-A-Velha, Portugal).
The H. pylori isolates were identiﬁed by colony morphology,
characteristic spiral morphology on Gram staining, and positive
catalase, urease and oxidase tests. Antrum and corpus samples
were processed separately.
The MIC for amoxicillin, clarithromycin, metronidazole,
levoﬂoxacin and tetracycline were determined by Etest
(bioMerieux Portugal) and expressed in mg/L. To minimize
variations in the results, H. pylori ATCC 43504 was used for
quality control of the susceptibility assay and a different
microbiologist, blinded to previous results, repeated all tests.
Strains were considered resistant to amoxicillin, clarithromycin,
metronidazole, levoﬂoxacin and tetracycline at MIC >0.5, >1,
>8, >1, and >1 mg/L, respectively. MIC values were established
according to the data available in 2009, including the CLSI
breakpoints [3,12–15]. A strain was considered multidrug-
resistant if it had resistance to two or more antibiotics.
DNA extraction from pure culture of H. pylori was
performed with a special extraction kit (QIAamp DNA Mini
Kits, QIAGEN, Izasa Portugal, Carnaxide, Portugal) according
to the manufacturer’s instructions. Point mutations in 23S
rRNA (A2143G/A2142G, A2142C), the quinolone resis-
tance-determining region (QRDR) of the gyrA and the 16S
rRNA genes were detected by real-time PCR using a LightCy-
cler device, as previously described [13,16,17].
The cagA, vacA, iceA and babA2 genotypes were determined
with real-time PCR by using speciﬁc primers selected from
previously published works [18–20].
Statistics
Categorical variables were presented with their relative and
absolute values and quantitative ones were expressed as
mean  standard deviation or median + range. For statistical
analysis, Student’s t-test, Mann–Whitney and Fisher’s exact
test were used. Signiﬁcant variables were subsequently
included in a binary logistic regression analysis to determine
independent risk factors for resistance to each antibiotic. The
statistical software package SPSS 20.0 for Windows (SPSS,
Chicago, IL, USA) was used.
Ethical considerations
The study was approved by the ethics committee of our
Hospital and the Faculty of Medicine, and was performed in
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accordance with all standards of good clinical practice. Signed
informed consent was obtained from each patient.
Results
A total of 180 patients (131 female; mean age 43.4  13.5 years;
Group I 103; Group II 77) were included. Demographic and
clinical characteristics are presented in Table 1. For the 77
previously treated patients the median number of eradication
attempts was one (range one to six) with the following
drugs: amoxicillin, 77 (100%); clarithromycin, 73 (94.8%);
nitroimidazoles, 24 (31.2%); levoﬂoxacin, 12 (15.6%).
Endoscopy with biopsies was successfully and safely per-
formed in all patients. We obtained 360 H. pylori isolates
(antrum, 180; corpus, 180) and in eight patients there were
differences between isolates from the antrum and the corpus,
concerning mutations for 23S rRNA genes and resistance to
clarithromycin. We considered only one isolate for each
patient, always selecting the one with resistance.
Global, primary and secondary resistance rates are pre-
sented in Table 2. The only strain resistant to amoxicillin had a
MIC level of 2 mg/L.
Genotyping revealed mutations in 23S rRNA in 86 isolates
(47.8%), in the QRDR region of the gyrA gene in 50 (27.8%)
isolates, and mutations in 16S rRNA in four isolates (2.2%), two
AGA926–928-GGA, one AGA926–928-GTA and another
AGA926–928-TTC. For the ﬁrst two, the MIC level was
0.016 mg/L, for the third it was 0.094 mg/L and for the last
one it was 32 mg/L. So, only this isolate had in vitro resistance
to tetracycline. For technical reasons it was not possible to
study the gyrA gene in three isolates with resistance to
levoﬂoxacin. Mutations in 23S rRNA and gyrA genes were
detected in 86 (95.6%) and 50 (86.2%) of the isolates with in
vitro resistance to clarithromycin and levoﬂoxacin, respectively.
The cagA gene was detected in 63 strains (35%), the vacA
s1m1 in 34 (18.9%), s1m2 in 48 (26.7%), s2m1 in 3 (1.7%) and
s2m2 in 95 (52.7%). The gene iceA1 was positive in 71 (39.4%)
isolates and babA2 in 21 (11.7%). The distribution of vacA
genotypes according to cagA status is presented in Table 3.
Clinical characteristics and bacterial genotypes associated
with resistance to clarithromycin, metronidazole and levoﬂox-
acin are resumed in Table 4. There were no signiﬁcant
differences for ethnic background, place of residence, non-
ulcer dyspepsia, need for chronic therapy with PPI, iron-deﬁ-
TABLE 1. Demographic and clinical characteristics of the
patients
Group I
n = 103
Group II
n = 77 p value
Mean age (years) 41.6  12.9
(range 19–77)
45.8  14.1
(range 18–85)
0.039
Gender (%)
Male 30 (29.1) 19 (24.7) 0.612
Female 73 (70.9) 58 (75.3)
Ethnic background (%)
European 99 (96.1) 76 (98.7) 0.394
African 4 (3.9) 1 (1.3)
Education level (%)
Level 1 30 (29.1) 33 (42.9) 0.06
Level 2 73 (70.9) 44 (57.1)
Residence (%)
Rural 55 (53.4) 47 (61) 0.362
Urban 48 (46.6) 30 (39)
Indication(s) for Helicobacter pylori eradication (%)
Non-ulcer dyspepsia 63 (61.2) 53 (68.8) 0.346
GERD/Chronic therapy
with PPI
24 (23.3) 22 (28.6) 0.491
First-degree relatives
with gastric cancer
14 (13.6) 15 (19.5) 0.311
Iron-deﬁcient anaemia 25 (24.3) 10 (13) 0.086
Peptic ulcer 9 (8.7) 7 (9.1) 1
BMI (kg/m2) 24.6  4.2
(range 17.1–37.8)
25.2  4.1
(range 17.1–33.8)
0.371
Smoking (%) 13 (12.6) 17 (22.1) 0.108
Alcohol consumption (%) 21 (20.4) 19 (24.7) 0.587
Olive oil consumption
<1 dL/week (%)
50 (48.5) 40 (51.9) 0.763
History of frequent
infections (%)
20 (19.4) 18 (23.4) 0.581
Antibiotic consumption in
the last 12 months (%)
28 (27.2) 60 (77.9) <0.0001
Family history of gastric
diseases (%)
49 (47.6) 42 (54.5) 0.370
Family history of H. pylori
infection (%)
10 (9.7) 9 (11.7) 0.807
BMI, Body Mass Index; GERD, gastro-oesophageal reﬂux disease; PPI, pro-
ton-pump inhibitors; Level 1, No education/Primary grades (Primary school); Level
2, Secondary grades (High-school)/University level.
TABLE 2. Pattern of resistance for the 180 isolates (one per
patient)
Resistance
Total
(n = 180)
(%)
Group I
(n = 103)
(%)
Group II
(n = 77)
(%) p value
Amoxicillin 1 (0.6) 1 (1) 0 (0) 1
Clarithromycin 90 (50) 22 (21.4) 68 (88.3) <0.0001
Tetracycline 1 (0.6) 0 (0) 1 (1.3) 0.428
Metronidazole 62 (34.4) 30 (29.1) 32 (41.6) 0.113
Levoﬂoxacin 61 (33.9) 27 (26.2) 34 (44.2) 0.017
No resistance 52 (28.9) 47 (45.6) 5 (6.4) <0.0001
Single resistance 61 (33.9) 36 (35) 25 (32.5) 0.753
Dual resistance 49 (27.2) 17 (16.5) 32 (41.6) <0.0001
Triple resistance 17 (9.4) 3 (2.9) 14 (18.2) 0.001
Quadruple resistance 1 (0.6) 0 (0) 1 (1.3) 0.428
Multidrug-resistant 67 (37.2) 20 (19.4) 47 (61) <0.0001
Clarithromycin +
Metronidazole
36 (20) 6 (5.8) 30 (39) <0.0001
Clarithromycin +
Levoﬂoxacin
41 (22.8) 9 (8.7) 32 (41.6) <0.0001
Metronidazole +
Levoﬂoxacin
26 (14.4) 11 (10.7) 15 (19.5) 0.133
TABLE 3. vacA genotype distribution according to cagA
status
Genotype
cagA-positive
(n = 63) (%)
cagA-negative
(n = 117) (%) p value
s1m1 28 (44.4) 6 (5.1) <0.0001
s1m2 22 (34.9) 26 (22.2) 0.076
s2m1 2 (3.2) 1 (1.7) 1
s2m2 11 (17.5) 84 (71.8) <0.0001
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cient anaemia, peptic ulcer, body mass index, tobacco/alcohol/
olive oil consumption, vacA s1m2, vacA s2m1 and iceA1
genotypes. Variables from Table 4 were subsequently included
in a multivariate analysis that revealed the following positive
relations: clarithromycin resistance with female sex
(OR = 3.28; 95% CI 1.07–10.05) and previous, failed
eradication treatments (OR = 31.32; 95% CI 10.06–98.48);
metronidazole resistance with female sex (OR = 2.78; 95% CI
1.23–6.26); levoﬂoxacin resistance with history of frequent
infections (OR = 2.61; 95% CI 1.19–5.71); ﬁrst-degree
relatives with gastric carcinoma (OR = 2.63; 95%
CI 1.10–6.26); and low education levels (OR = 2.43; 95% CI
1.21–4.85).
Discussion
The effectiveness of most commonly recommended H. pylori
eradication treatments has declined to unacceptablly low levels
[2]. So, it is important to periodically determine the resistance
patterns in a certain region to establish what are the best
therapy combinations to eliminate this bacterium.
In Portugal, H. pylori resistance rates can be as high as
39.4% for clarithromycin, 33.3% for metronidazole and 26.3%
for levoﬂoxacin. Resistance to amoxicillin and tetracycline are
very rare [5,7,10,21,22]. Data about secondary resistance are
scarce although Cabrita et al. [21] reported, in 2000, values of
75% and 47% for metronidazole and clarithromycin, respec-
tively. To the best of our knowledge these data were
obtained in the metropolitan area of Lisbon and there is no
information about this problem in the central region of
Portugal. With the present study we established that in this
part of the country primary resistance rates to metronidazole
and levoﬂoxacin are comparable to the ones published
recently by Megraud et al. [5]. Primary resistance to clar-
ithromycin is lower than reported in the same study (21.4%
versus 31.5%) but it surpasses the value established as the
limit to allow empiric triple therapy with this antibiotic [1].
Resistance rates were higher in patients with failed eradica-
tions and, in this group, are similar to the ones reported in
the literature, ranging from 40–70% for metronidazole, 50–
85% for clarithromycin and multidrug-resistant in 51–90%
[6,23–25]. This is very problematic because, in Portugal, many
anti-H. pylori drugs such as bismuth, tetracycline, furazolidone,
nitazoxanide and rifabutin are unavailable or cannot be used.
It is of crucial importance to choose the most effective
regimen on each occasion because failures are potentially
untreatable.
Only the strain with the triple base-pair substitution
AGA926–928-TTC had tetracycline resistance and, in contrast
to what is reported in the literature, the isolate with AGA926–
928-GTA had MIC levels within the susceptible range [17]. We
also isolated only one strain resistant to amoxicillin, conﬁrming
the high levels of H. pylori susceptibility to this antibiotic in all
circumstances.
The secondary resistance rate to clarithromycin was higher
than previously reported for Portugal but similar to results
from other European countries [21,26]. Mutations in 23S rRNA
were identiﬁed in 95.6% of isolates with phenotypic resistance.
We only studied the three classic mutations described in the
literature that are responsible for >90% of clarithromycin-
resistant clinical strains but there are several other point
mutations in 23S rRNA, some of them associated with low
resistance levels [4,27]. So, it is possible that the four strains
with in vitro resistance and no genotypic alterations could have
any of such mutations or there could be other responsible
mechanisms such as the efﬂux pump system [27].
Resistance rates to metronidazole were high but did not
increase signiﬁcantly in patients with unsuccessful eradication
attempts. This can be explained because failed treatments with
nitroimidazoles do not systematically determine resistance.
On the other hand, we should not forget that metronidazole
susceptibility testing by Etest can overestimate resistance by
10 to 20% in comparison with the agar dilution method [12].
We tried to overcome this problem by using a control strain
and repeating the test by a different microbiologist.
Primary and secondary resistance rates to levoﬂoxacin are
worrisome. The high values detected for primary resistance
are probably explained because ﬂuoroquinolones are widely
employed for the treatment of other common bacterial
infections and our country has high levels of outpatient
antibiotic consumption. It is possible that loss of susceptibility
was determined by pre-treatment H. pylori exposure to
inadequate levels of antimicrobials [5,26,28]. This is a limitation
of our work because, for group II, we had no data about
antibiotic susceptibility before eradication treatments.
High macrolide and ﬂuoroquinolone consumption for minor
respiratory and urinary infections can also explain why
resistance to clarithromycin and levoﬂoxacin is higher in older
individuals, given the cumulative probability of exposure to
such drugs. Megraud et al. [5] also found that older age was a
risk factor for levoﬂoxacin resistance.
Presence of gyrA mutations was associated with resistance
to levoﬂoxacin but not all isolates with lack of in vitro
susceptibility had genotypic alterations. This can occur because
we did not test all possible mutations. It would be important to
sequence QRDR in genes gyrA and gyrB to conﬁrm these
possible associations.
Women more frequently have H. pylori strains resistant to
macrolides, ﬂuoroquinolones and nitroimidazoles. This ﬁnding
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is consistent with other studies and is determined by the
increased use of antimicrobials in women to treat gynaeco-
logical and urinary infections.
Patients with lower educational levels had increased
H. pylori resistance to clarithromycin and levoﬂoxacin. We
can speculate that they had lower socioeconomic status and
eventually more unnecessary exposure to antibiotics. How-
ever, we have no data to explain these differences and a more
consistent epidemiological approach would be necessary to
conﬁrm these results.
Our data did not support a correlation of clinical presentation
with antibiotic resistance but one major limitation of our study is
the high number of patients with non-ulcer dyspepsia [5]. We
found no plausible explanation for the association between
resistance to levoﬂoxacin and ﬁrst-degree relatives with gastric
cancer and this must be conﬁrmed in other studies.
Our study revealed the possibility of mixed infection by
antibiotic hetero-resistant H. pylori. This was already reported
in the literature and a resistant strain in any site of the stomach
is enough to determine treatment failure [23,29]. For that
reason, we suggest that in H. pylori antibiotic susceptibility
testing it is important to obtain samples from at least two
different locations and these biological materials must be
processed independently.
The genes cagA and vacA have been identiﬁed as the main
H. pylori virulence factors. There are reports of a strong
association between eradication success, antibiotic suscepti-
bility and these virulence factors, mainly for clarithromycin
[4,30]. The present study also indicated that s2m2 strains,
which are mostly cagA negative, seem to be more resistant to
clarithromycin and metronidazole than strains with the s1m1
and s1m2 combinations.
Conclusions
Primary and secondary resistance rates to clarithromycin,
metronidazole and levoﬂoxacin are very high in the central
region of Portugal and, at least for clarithromycin, are
associated with previous eradication treatments. In contrast,
resistance rates to amoxicillin and tetracycline are negligible,
even after systematic use of amoxicillin.
In vitro resistance to clarithromycin and levoﬂoxacin can be
predicted in most cases by the presence of speciﬁc mutations.
Molecular methods for determining resistance in biopsy or
stool specimens could be very useful in clinical practice,
potentially avoiding expensive and time-consuming cultures.
Multidrug-resistant isolates are common and probably, the
quadruple concomitant or quadruple hybrid therapies are the
best options for ﬁrst-line treatment in Portugal.
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